Search
Nov 17
With programs using both somatic cells and iPSCs, and an NK platform for oncology in the works, Japan's Healios aims to be a leader in regenerative medicine
CEO Hardy Kagimoto describes the company's programs, including how Multistem could soon be conditionally approved in Japan and is...